About the Company
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BBIO News
What's Going On With BridgeBio Pharma Stock On Monday?
BridgeBio Pharma Inc (NASDAQ:BBIO) and Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced a partnership wherein BridgeBio grants ...
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical ...
BridgeBio Pharma Commences Public Offering Of $250 Mln Of Shares; Stock Down
(RTTNews) - BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, said that it has commenced an underwritten public offering of $250 ...
BridgeBio Pharma Prices Offering Of $250 Mln Of Shares
BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases and cancers, on Wednesday announced the pricing of public ...
2 Bay Area biotechs look to raise collective $550 million following deal, trial news
These Bay Area biotechs are hoping to raise $550 million between them on the back of some positive news developments. Here's ...
BridgeBio Pharma Inc BBIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BridgeBio Pharma Stock (NASDAQ:BBIO), Quotes and News Summary
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its ...
BridgeBio Pharma: Q4 Earnings Snapshot
PALO ALTO, Calif. — PALO ALTO, Calif. — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $168.1 million in its fourth quarter. The Palo Alto, California-based company said it had a ...
BridgeBio Pharma Inc BBIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...